ARS Pharmaceuticals beats Q4 2025 EPS and revenue estimates with non-GAAP EPS -$0.41 (-185% YoY) and revenue $28.1M (-68% YoY)
- Full-year 2025 revenue totaled $84.3M, alongside previously disclosed Q4 revenue of $28.1M.
- Year-end cash of $245 million is expected to fund operations through anticipated cash-flow break-even.
- Company provided an update on neffy commercialization progress as part of its Q4 2025 report.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.